COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
Ivermectin study #43 of 63
12/20 Prophylaxis study
Vallejos et al., Trials, doi:10.1186/s13063-020-04813-1 (Preprint)
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial
Source   PDF   Share   Tweet
Report on ivermectin + carrageenan prophylaxis in a hospital in Argentina showing lower cases for healthcare workers taking ivermectin. The effect is likely to be primarily due to ivermectin - the creator of the protocol has later reported that carrageenan is not necessary [1]. Preliminary results from: [2].

Vallejos et al., 12/20/2020, retrospective, Argentina, South America, preprint, 1 author, dosage 12mg weekly.
risk of COVID-19 case, 73.6% lower, RR 0.26, p < 0.001, treatment 11 of 389 (2.8%), control 52 of 486 (10.7%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 63 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit